Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active then Sham Treatment Clear all
Completed Not applicable Interventional Results available

Cognitive Outcomes of Brain Stimulation As a Later-in-Life Treatment

NCT05564715
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Impairment - aMCI
Interventions
NeuroElectric StarStim, Sham Treatment
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for MCI

NCT05992831
View directory record Official record
Conditions
Mild Cognitive Impairment, Depression
Interventions
Accelerated iTBS, Sham Comparator
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
60 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 15, 2026, 2:04 AM EDT
Recruiting Phase 2 Interventional

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

NCT04060030
View directory record Official record
Conditions
Autism Spectrum Disorder, Language Disorders
Interventions
Levoleucovorin Calcium, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
30 Months to 60 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157
View directory record Official record
Conditions
Verruca Vulgaris, Warts, Common Wart
Interventions
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
9 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 15, 2026, 2:04 AM EDT
Withdrawn Not applicable Interventional

Lidocaine Patch for Relief of Pain During Epidural Placement in Laboring Patients

NCT01307839
View directory record Official record
Conditions
Pregnant, Labor
Interventions
5% lidocaine patch, placebo patch
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03693430
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 15, 2026, 2:04 AM EDT
Not listed Phase 1Phase 2 Interventional

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

NCT04815902
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
40 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 15, 2026, 2:04 AM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

NCT01272388
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Trauma Related Insomnia

NCT02704754
View directory record Official record
Conditions
Insomnia, Posttraumatic Stress Disorder
Interventions
suvorexant, placebo
Drug · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 15, 2026, 2:04 AM EDT
Not listed Phase 2 Interventional

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

NCT02511873
View directory record Official record
Conditions
Neuropathy, Small Fiber
Interventions
Fycompa, Placebo
Drug
Lead sponsor
PNA Center for Neurological Research
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Role of Home-Based Transcutaneous Electrical Acustimulation for Treatment of Pain in Subjects With Chronic Pancreatitis

NCT06721572
View directory record Official record
Conditions
Chronic Pancreatitis, Pancreatitis
Interventions
TEA
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02579239
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy
Interventions
ATYR1940, Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Irvine, California • Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Eptinezumab in Participants With Episodic Cluster Headache

NCT04688775
View directory record Official record
Conditions
Cluster Headache, Episodic
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

NCT03552757
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide), Placebo II (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
50
States / cities
Buena Park, California • Concord, California • Fresno, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

RNS® System Feasibility Study

NCT00079781
View directory record Official record
Conditions
Epilepsy
Interventions
RNS® System implantation, RNS® System responsive stimulation
Procedure · Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

NCT03078907
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 2:04 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Topical Cannabidiol Cream and Post-exercise Recovery

NCT05044936
View directory record Official record
Conditions
Muscle Damage
Interventions
Cannabidiol Oil, Resistance Exercise
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 15, 2026, 2:04 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

NCT01610765
View directory record Official record
Conditions
Herpes Simplex Virus
Interventions
Novel Antiviral Drug, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 98 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Fecal Transplant for Ulcerative Colitis

NCT03948919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal microbiota, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 15, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

NCT02358694
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Serum-Derived Bovine Immunoglobulin, Placebo
Dietary Supplement · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 15, 2026, 2:04 AM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 15, 2026, 2:04 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

NCT06334016
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Biospecimen Collection, Cannabis sativa Extract, Nicotine, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 2:04 AM EDT